Provided by Tiger Trade Technology Pte. Ltd.

Lexicon Pharmaceuticals

2.25
-0.0400-1.75%
Volume:6.65M
Turnover:14.91M
Market Cap:999.00M
PE:-14.17
High:2.29
Open:2.27
Low:2.19
Close:2.29
52wk High:2.68
52wk Low:1.03
Shares:444.00M
Float Shares:220.42M
Volume Ratio:3.70
T/O Rate:3.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1587
EPS(LYR):-0.1387
ROE:-40.21%
ROA:-14.32%
PB:5.72
PE(LYR):-16.23

Loading ...

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

GlobeNewswire
·
Jul 30

Lexicon Pharmaceuticals: Advancing Cardiometabolic Pipeline and Phase 3 HCM Data Support Unchanged $6 Price Target and Buy Rating

TIPRANKS
·
Jul 27

Lexicon completes enrollment in SONATA-HCM study

TIPRANKS
·
Jul 27

Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment

MT Newswires Live
·
Jul 27

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 Sonata-Hcm Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (Hcm)

Reuters
·
Jul 27

Lexicon Pharmaceuticals - Topline Results for Sonata-HCM Trial Anticipated in Q1 2027

THOMSON REUTERS
·
Jul 27

How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX)

Simply Wall St.
·
Jul 02

Lexicon presents new sotagliflozin Type 1 diabetes subgroup analysis at ADA 2026 sessions

Reuters
·
Jun 03

Lexicon Pharmaceuticals’ Earnings Call Highlights Milestone-Fueled Surge

TIPRANKS
·
Jun 02

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

GlobeNewswire
·
May 28

Stock Track | Lexicon Pharmaceuticals Soars 5.63% Intraday on Investor Conference Participation Announcement

Stock Track
·
May 12

Lexicon Pharmaceuticals to present at H.C. Wainwright BioConnect Investor Conference

Reuters
·
May 12

Lexicon Pharma Is Maintained at Buy by Citigroup

Dow Jones
·
May 11

Lexicon Pharmaceuticals: Buy Rating Reiterated as Value Catalysts Build; $6 Price Target Maintained

TIPRANKS
·
May 08

Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Lexicon Q1 FY26 net loss narrows to $1 million; revenue rises to $21.1 million

Reuters
·
May 07

Lexicon Pharmaceuticals Q1 Sales $1.090M Miss $9.380M Estimate

Benzinga Earnings
·
May 07

BRIEF-Lexicon Pharmaceuticals Q1 EPS USD -0.01

Reuters
·
May 07

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

GlobeNewswire
·
May 07

Lexicon Pharmaceuticals Secures New Hercules Term Loan Facility

TIPRANKS
·
May 07